Screener
XPH vs IBB
State Street SPDR S&P Pharmaceuticals ETF vs iShares Biotechnology ETF
Key differences
- XPH costs 0.09% less per year.
- IBB is significantly larger than XPH — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, XPH has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| XPH | IBB | |
|---|---|---|
| Annual cost (TER) | 0.35% | 0.44% |
| Fund size (AUM) | $355M | $7.9B |
| Since | 2006 | 2001 |
| Dividend yield | 0.65% | 0.23% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +46.3% | +39.0% |
| CAGR 3Y | +13.8% | +9.6% |
| CAGR 5Y | +4.5% | +2.7% |
| Sharpe 3Y | 0.57 | 0.38 |
| Volatility 1Y | 21.29% | 19.75% |
| Max drawdown | -35.96% | -39.82% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to XPH and IBB
Explore further